Johnson & Johnson delivered strong full-year results, surpassing earnings expectations and demonstrating robust segment performance. While the 2019 sales guidance indicates slight declines due to currency and generic pressures, the positive earnings outlook and stock repurchase program suggest investor confidence. Overall, these factors are likely to have a positive short-term impact on the stock.

[1]